The price to earnings ratio: When cheap means crap
There are key differences between earnings growth and price-earnings. Knowing them could spell success or failure to investors in stock market.
Everyone loves cheap, especially investors. But when cheap becomes crap, cheap becomes expensive. In the stock market, investors are seduced by low-quality stocks looking cheap and promising at first sight. The moment of happiness lasts until they realize that the stock’s performance is moderate at best. And low-quality stocks often result in capital losses and dividend cuts.
A notorious dazzler
Dividing price by earnings is a common metric to determine a stock’s valuation. Unfortunately, “common” does not equal “correct.” In an open market, whenever something looks cheap, something is rotten. The stock market is one of the most open markets, thus cheap means something must be very rotten.
Don’t believe? Let’s have a look what “cheap” really means.
How cheap looks like
These charts show the relationship between earnings growth and price-earnings. As earnings decline, the stock price declines even faster, leading to a contraction of the price-earning-ratio. The stock becomes “cheap” because the company is in serious “earnings” trouble, and the market does not believe in fast recovery.
The stock price tumbled from above $70 in 2014 to less than $23 now. A painful capital loss for anybody invested. If you “took the chance” and bought in 2017 when the price-earnings-ratio was “only” 10, you still lost about 50 percent. Sole consolation: when all earnings are gone, there is no price-earnings-ratio anymore.
No price-earnings-ratio — then what?
Long-term investors should always invest in high-quality stocks, but the price-earnings-ratio has no clue about quality. That’s the problem, and that’s why we need other metrics. Which one, I’ll tell another time.
P.S.: The same goes for the price-to-book-ratio.
DISCLAIMER: This article expresses my own ideas and opinions. Any information I have shared are from sources that I believe to be reliable and accurate. I did not receive any financial compensation in writing this post, nor do I own any shares in any company I’ve mentioned. I encourage any reader to do their own diligent research first before making any investment decisions.
Adult-Use Cannabis Could Soon Be Legalized in Colombia
Colombia is one step closer to the legalization of adult-use cannabis. Many parliamentarians who were previously fervently opposed to the...
Why Ripple Registered a 29% Weekly Increase
The number of daily transactions on Ripple recently reached 2.3 million, the highest in 16 months. At the same time,...
Moderna Will Pay $70 Million to Generation Bio for Genetic Medicines
Moderna closed 2022 with a profit of $8.36 billion, which represents a decrease of 31% compared to the previous year....
Cotton Demand Has Been Ramping Up for the Last Couple of Months but Fell Off
Cotton was lower and closed at new lows for the move. Chart trends turned down again with the price action...
The US Equity Crowdfunding Platform WeFunder Launches in Europe
Unlike the other platforms, WeFunder has taken a "soft" approach compared to, for example, Republic's $100 million acquisition of Seedrs,...
Biotech2 weeks ago
GenomeUp Closes 1.5 Million Round Led by Scientifica and Lazio Innova
Cannabis6 days ago
The Market for CBD Skincare Products Is Gaining Popularity
Biotech2 weeks ago
Prometheus Surpasses the Minimum Target of 1.6 Million in 24h
Business1 day ago
Stock Market Goes Nowhere Fast, as Gold Approaches a New All-Time High
You must be logged in to post a comment Login